Koers OHR Pharmaceutical Inc Nasdaq
Aandelen
US67778H2004
Biotechnologie & Medisch Onderzoek
Omzet 2023 * | - | Omzet 2024 * | - | Marktkapitalisatie | 1,56 mln. 1,46 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2023 * | -12 mln. -11,24 mln. | Nettowinst (verlies) 2024 * | - | EV/omzet 2023 * | - |
Nettoliquiditeiten 2023 * | - 0 | Nettoliquiditeiten 2024 * | - 0 | EV/omzet 2024 * | - |
K/w-verhouding 2023 * |
-0,06
x | K/w-verhouding 2024 * |
-
| Werknemers | - |
Dividendrendement 2023 * |
-
| Dividendrendement 2024 * |
-
| Vrij verhandelbaar | 86,62% |
Recentste transcriptie over OHR Pharmaceutical Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Todd Branning
CEO | Chief Executive Officer | 54 | 10-01-22 |
Dani Stoltzfus
PRN | Corporate Officer/Principal | - | - |
Ron Sarkar
PRN | Corporate Officer/Principal | - | 01-11-21 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Dov Goldstein
CHM | Chairman | 56 | 12-07-19 |
Eric Richman
BRD | Director/Board Member | 63 | 12-07-19 |
Director/Board Member | 79 | 12-07-19 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+20,36% | 42,68 mld. | |
-2,23% | 42,4 mld. | |
+45,09% | 40,04 mld. | |
-6,20% | 28,31 mld. | |
+5,13% | 24,94 mld. | |
-20,30% | 18,96 mld. | |
+30,66% | 12,3 mld. | |
-3,22% | 11,95 mld. | |
-4,07% | 11,55 mld. |